Literature DB >> 23581255

Serum metabolomics reveals lipid metabolism variation between coronary artery disease and congestive heart failure: a pilot study.

Hemi Luan1, Xiaomin Chen, Shilong Zhong, Xune Yuan, Nan Meng, Jianfeng Zhang, Jin Fu, Ran Xu, Connie Lee, Siyuan Song, Hui Jiang, Xun Xu.   

Abstract

The aim of this pilot study is to find discriminating signals from the patient's congestive heart failure (HF) caused by coronary artery disease (CAD) through a non-target metabolomics method and test their usefulness in progress of human HF diseases. Multivariate data analysis was used to identify the discriminating signals. Interestingly, 12 metabolites contributing to the complete separation of HF from matched CAD were identified. Metabolic pathways including free fatty acids, sphingolipids and amino acid derivatives were found to be disturbed in HF patients compared with CAD patients. Lipid molecules associated with energy metabolism and signaling pathways may play key roles in the development of failing heart.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23581255     DOI: 10.3109/1354750X.2013.781222

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  6 in total

1.  Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention.

Authors:  Ruixin Liu; Jie Hong; Xiaoqiang Xu; Qiang Feng; Dongya Zhang; Yanyun Gu; Juan Shi; Shaoqian Zhao; Wen Liu; Xiaokai Wang; Huihua Xia; Zhipeng Liu; Bin Cui; Peiwen Liang; Liuqing Xi; Jiabin Jin; Xiayang Ying; Xiaolin Wang; Xinjie Zhao; Wanyu Li; Huijue Jia; Zhou Lan; Fengyu Li; Rui Wang; Yingkai Sun; Minglan Yang; Yuxin Shen; Zhuye Jie; Junhua Li; Xiaomin Chen; Huanzi Zhong; Hailiang Xie; Yifei Zhang; Weiqiong Gu; Xiaxing Deng; Baiyong Shen; Xun Xu; Huanming Yang; Guowang Xu; Yufang Bi; Shenghan Lai; Jian Wang; Lu Qi; Lise Madsen; Jiqiu Wang; Guang Ning; Karsten Kristiansen; Weiqing Wang
Journal:  Nat Med       Date:  2017-06-19       Impact factor: 53.440

Review 2.  Metabolic Dysfunction in Heart Failure: Diagnostic, Prognostic, and Pathophysiologic Insights From Metabolomic Profiling.

Authors:  Wynn G Hunter; Jacob P Kelly; Robert W McGarrah; William E Kraus; Svati H Shah
Journal:  Curr Heart Fail Rep       Date:  2016-06

3.  Non-targeted metabolomics and lipidomics LC-MS data from maternal plasma of 180 healthy pregnant women.

Authors:  Hemi Luan; Nan Meng; Ping Liu; Jin Fu; Xiaomin Chen; Weiqiao Rao; Hui Jiang; Xun Xu; Zongwei Cai; Jun Wang
Journal:  Gigascience       Date:  2015-04-09       Impact factor: 6.524

4.  Nuclear magnetic resonance-based metabolomics identifies phenylalanine as a novel predictor of incident heart failure hospitalisation: results from PROSPER and FINRISK 1997.

Authors:  Christian Delles; Naomi J Rankin; Charles Boachie; Alex McConnachie; Ian Ford; Antti Kangas; Pasi Soininen; Stella Trompet; Simon P Mooijaart; J Wouter Jukema; Faiez Zannad; Mika Ala-Korpela; Veikko Salomaa; Aki S Havulinna; Paul Welsh; Peter Würtz; Naveed Sattar
Journal:  Eur J Heart Fail       Date:  2017-12-11       Impact factor: 15.534

5.  Integrated metabolomics and metagenomics analysis of plasma and urine identified microbial metabolites associated with coronary heart disease.

Authors:  Qiang Feng; Zhipeng Liu; Shilong Zhong; Ruijun Li; Huihua Xia; Zhuye Jie; Bo Wen; Xiaomin Chen; Wei Yan; Yanqun Fan; Zhenyu Guo; Nan Meng; Jiyan Chen; Xiyong Yu; Zhiwei Zhang; Karsten Kristiansen; Jun Wang; Xun Xu; Kunlun He; Guanglei Li
Journal:  Sci Rep       Date:  2016-03-02       Impact factor: 4.379

6.  ALT-to-Lymphocyte Ratio as a Predictor of Long-Term Mortality in Patients with Normal Liver Function Presenting Coronary Artery Disease after Undergoing PCI: A Retrospective Cohort Study.

Authors:  Ru-Jie Zheng; Qian-Qian Guo; Jun-Nan Tang; Xu-Ming Yang; Jian-Chao Zhang; Meng-Die Cheng; Feng-Hua Song; Zhi-Yu Liu; Kai Wang; Li-Zhu Jiang; Lei Fan; Xiao-Ting Yue; Yan Bai; Xin-Ya Dai; Zeng-Lei Zhang; Ying-Ying Zheng; Jin-Ying Zhang
Journal:  J Interv Cardiol       Date:  2020-04-21       Impact factor: 2.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.